postpartum haemorrhage prevention
Conditions
Interventions
Efficacy and safety of intrauterine 400 mcg of misoprostol to prevent primary postpartum haemorrhage
Insertion of 600 mcg of misoprostol
Sponsors
Self
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion Criteria • Singleton gestation billed for CS • Gestational ages of 37- 42 weeks
Exclusion criteria
Exclusion criteria: Exclusion Criteria • History of prostaglandin allergy • Antepartum haemorrhage (abruption placenta,placenta praevia, vasa praevia) • Multiple pregnancy • Obstructed labour • Sickle Cell Disease • Pre-eclampsia with HELLP syndrome • Pregnancy with coagulopathy • Intrauterine foetal death with coagulopathy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome Measures is the estimation of blood loss during and after caesarean section following administration of oxytocin and various doses of intrauterine misoprostol. Secondary outcome measures includes: •Postpartum drop in haematocrits (48 hours post delivery) •Need for blood transfusion (before discharge) •Need for additional oxytocic or surgical intervention for PPH (within 24 hours of delivery) •Misoprostol-related adverse effects such as shivering, vomiting, nausea, diarrhoea, pyrexia (Body Temperature >38*C), hyperpyrexia (Body Temperature >40*C) will be evaluated. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of misoprostol; need for additional uterotonic and packed cell volume | — |
Countries
Nigeria
Contacts
Public ContactChinyere Nwankwo
Registrar
Outcome results
None listed